Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1021 to 1035 of 1373 results for social care

  1. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

    Technology appraisal guidance
    Published
    25 May 2011
    View recommendations

    Sections for TA223

  2. Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]

    Discontinued Reference number: GID-TA10203

    Technology appraisal guidance
    Discontinued

  3. Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

    In development Reference number: GID-TA10405 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

    Medical technologies guidance
    Discontinued

  5. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued Reference number: GID-TA10437

    Technology appraisal guidance
    Discontinued

  6. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued Reference number: GID-TA10447

    Technology appraisal guidance
    Discontinued

  7. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued Reference number: GID-TA10892

    Technology appraisal guidance
    Discontinued

  8. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued Reference number: GID-TA10811

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

    Technology appraisal guidance
    Discontinued

  10. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

    Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 March 2019
    View recommendations

    Sections for TA569

  11. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued Reference number: GID-TA10277

    Technology appraisal guidance
    Discontinued

  12. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued Reference number: GID-TA10590

    Technology appraisal guidance
    Discontinued

  13. Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy [ID1147]

    Discontinued Reference number: GID-TA10343

    Technology appraisal guidance
    Discontinued

  14. Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]

    Discontinued Reference number: GID-TA10870

    Technology appraisal guidance
    Discontinued

  15. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

    Technology appraisal guidance
    Discontinued